Summary To assess the role of oestrogen regulation in the growth of ovarian cancer, we examined the effects of an oestrogen, 17 P-oestradiol, and an anti-oestrogen, tamoxifen, on oestrogen receptor (ER) -positive and -negative human ovarian carcinoma cell lines. As measured by a dextran-coated charcoal adsorption assay, cell lines PEOI, PEO4 (Schwartz et al., 1982; Pagel et al., 1983; Hamerlynck et al., 1985; Campbell et al., 1984) , although others have failed to demonstrate such benefits Slevin et al., 1986; Shirey et al., 1984; Landoni et al., 1983) .
The role of oestrogen in the growth of ovarian cancer is unclear. The presence of oestrogen receptors (ER) in the majority of ovarian tumours (Pollow et al., 1983; Jones et al., 1983; Ford et al., 1983; Slotman & Rao, 1988) (Schwartz et al., 1982; Pagel et al., 1983; Hamerlynck et al., 1985; Campbell et al., 1984) , although others have failed to demonstrate such benefits Slevin et al., 1986; Shirey et al., 1984; Landoni et al., 1983) .
We have recently derived and characterized a series of human ovarian carcinoma cell lines (Langdon et al., 1988) . In the present study, we measured the levels of ER in these lines and examined the effects of 17 P-oestradiol and the anti-oestrogen tamoxifen on the growth of two of these lines -the ER +ve line PE04 and the ER -ve line, PE014. We have also assessed the effects of high doses of tamoxifen on 8 of the lines of the series.
Materials and methods

Cell lines and drugs
The characterization of the cell lines has been described previously (Langdon et al., 1988) but brief details are recorded in Table I . Cell lines were routinely cultured at 37°C, 90% humidity and 5% CO2 in RPMI 1640 + fetal calf serum (FCS) (9:1) with streptomycin (100 gg ml-'), glutamine (2 mM), pyruvate (2 mM), penicillin (100 IU ml-'), and 3- [morpholino] propane sulphonic acid (12.5 mM, pH 7.4). 17 P-oestradiol was obtained from Sigma Ltd., Dorset, UK and tamoxifen was a gift from ICI Pharmaceuticals Ltd., Macclesfield, UK. In the cell growth experiments, both were initially dissolved in ethanol. The final concentration of ethanol in cell growth experiments was always less than 0.01 % v/v, a concentration previously shown to have no effect on these cell lines.
Oestrogen receptor assays Assays were performed on cells which were in early plateau phase of their growth using the dextran-coated charcoal adsorption method described previously (Hawkins et al., 1975; Hawkins et al., 1981 (Figure 1 ). This increased growth rate was similar to the growth rate of PEO4 cells in the presence of unstripped FCS (shown for days 4 and 7 in Figure 1 ). The stimulation by 0.1 nM 17 P-oestradiol could be completely blocked by simultaneous addition of 1 tiM tamoxifen (Figure 1 ). Since 1 0tM tamoxifen alone had no effect on control cells (Figure 1) (Figure 2) . After 4 days exposure to 17 p-oestradiol, 3H- thymidine incorporation into the wells of PEO4 cells was increased approximately 100% relative to the control group and this increased to approximately 280% at 7 days ( Figure  2 ). Again this effect was totally inhibited by tamoxifen while tamoxifen alone had no significant effect.
In contrast, the growth of the ER -ve PEO14 cell line was unaffected by addition of 17 ,B-oestradiol or tamoxifen (Figure 3 ). 3H-Thymidine uptake into the different groups of PEO14 cells was also unchanged by the presence or absence of 17p-oestradiol or tamoxifen (data not shown).
Effect of high-dose tamoxifen on cell growth To examine the cytostatic effects of tamoxifen, the cell lines were exposed to concentrations varying from I to 32 JM over 7 days. The selection of this dose range was based on a previous study which had investigated ER + ve and ER -ve breast carcinoma cell lines (Reddel et al., 1985) . Doses greater than 8 JAM were required to produce complete cytostasis in our ovarian cell lines (Table II) . There was no difference between ER + ve and ER -ve cell lines in their response to these high doses of tamoxifen.
To study the cytotoxic effects of tamoxifen, a colonyforming assay on plastic was used. Cell lines were exposed to tamoxifen for 72 hours and the IC50 dose varied between 5 and 11 JAM (Table II) . Again there was no significant difference between ER + ve and ER -ve lines.
Discussion
Results from clinical trials have yielded conflicting data as to the potential role of anti-oestrogen therapy for the treatment of ovarian cancer (Schwartz et al., 1982; Pagel et al., 1983; Hamerlynck et al., 1985; Campbell et al., 1984; Slevin et al., 1986; Shirey et al., 1984; Landoni et al., 1983) . To assess further the role of such therapy, we have examined the effects of oestrogen and tamoxifen on the growth of ER + ve and ER -ve oestrogen carcinoma cell The influence of 17 P-oestradiol on the growth of an ER + ve cell line, PE04, was examined to determine if there was evidence of oestrogen-sensitivity. Extrapolating from studies with breast cell lines, oestrogen-sensitivity is most clearly indicated under conditions where levels of oestrogen are first reduced in the growth medium (Reddel et al., 1984; Sutherland et al., 1983) . Addition of 17 P-oestradiol to charcoalstripped serum enhanced the growth rate of PE04 cells indicating sensitivity to oestrogen. This oestrogenic stimulus could be inhibited by the simultaneous presence of 1 IJM tamoxifen, providing further support that this is an ERmediated event. However, the PE04 cell line still grows under conditions where an oestrogenic stimulus is markedly reduced, that is, in phenol red-free medium containing charcoal-stripped serum. Also the presence, or absence, of phenol red appeared to have no effect on the growth rate of this cell line. It is possible that there is residual oestrogen after charcoal-stripping and that this is effective. However, the addition of tamoxifen alone to PE04 cells under these conditions did not produce further inhibition. Thus the cell line, while being oestrogen-sensitive, appears not to be oestrogen-dependent. The growth of PE014 cells, on the other hand, was not stimulated by oestrogen, or inhibited by anti-oestrogen, a property which is consistent with its lack of ERs. In the case of breast cancer, tamoxifen at doses greater than 5 lM is equally cytotoxic and cytostatic to cell lines, irrespective of ER content (Reddel et al., 1985) . The response of our ovarian lines to high levels of tamoxifen was examined in two ways. The cytotoxic effects of the drug were examined in a clonogenic assay. Doses of 5 to 11 JiM were toxic (measured as the IC5o) for all lines, whether ER + ve or ER-ve. This is also the dose range reported for cytotoxicity to a series of 13 breast carcinoma cell lines (Reddel et al., 1985) . In cell growth assays, doses of tamoxifen greater than 8 g.m were needed to prevent increase in the cell number.
Again ER + ve cell lines responded no differently from ER -ve lines. These concentrations affecting cell growth in vitro are above the maximum blood concentration of approximately 1 tLM that can be achieved in vivo, even when a loading dose of tamoxifen, to enhance blood and tumour levels, is used (Fabian et al., 1981) . In two previous studies, where ovarian carcinoma samples were grown in agar, increased concentrations of tamoxifen produced increased inhibition of colony formation, but this, too, was independent of ER status (Runge et al., 1986a; 1986b) . In another study, only 2 of 4 ovarian tumour samples which contained an ER concentration of greater than 30 fmol mg-' protein responded to a continuous exposure of 2ylM tamoxifen; all 14 samples with an ER content less than 30 fmol mg'-protein showed no response (Lazo et al., 1984) . These studies, together with our own, suggest that high levels of tamoxifen are needed to have a major inhibitory effect on the growth of ovarian carcinoma in vitro. As seen in this study with PEO4 cells, even when tamoxifen is able to antagonise completely oestrogen-stimulated growth, there remains an oestrogenindependent growth component which can only be abolished by very high concentrations of tamoxifen.
In conclusion, these series of cell lines represent a model system to assess further the role of endocrine therapy in ovarian cancer. To the best of our knowledge, they represent the first ovarian carcinoma cell lines reported with ER concentrations greater than 30 fmol mg-' protein (Hamilton et al., 1983) . As such, they are being used to help define the mechanisms by which oestrogen can modify growth in ovarian cancer.
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